Intellectual Disability, Autosomal Dominant 52 (MRD52): Research Report

Executive summary

Intellectual disability, autosomal dominant 52 (MRD52) is an ultra-rare, congenital neurodevelopmental chromatinopathy caused principally by heterozygous pathogenic variants in ASH1L, usually through loss of function or haploinsufficiency. The phenotype is variable but centers on developmental delay/intellectual disability, severe speech-language impairment, autism or other behavioral abnormalities, and sometimes hypotonia, dysmorphism, and epilepsy. ASH1L is a Trithorax-family histone lysine methyltransferase that promotes transcriptionally permissive chromatin, principally through H3K36 methylation and associated H3K4 methylation, while opposing Polycomb repression. No disease-specific therapy, validated biomarker, prevalence estimate, or dedicated clinical trial was identified. The most important 2024 advances are mechanistic: a peer-reviewed Ash1l-haploinsufficient mouse study implicated excessive prefrontal cortical excitability, while a December 2024 bioRxiv study found impaired neurite growth, transcription, and chromatin regulation in engineered human neurons. Both remain preclinical. (ma2024chemogeneticinhibitionof pages 12-13, wilson2022reprogrammingofthe pages 14-15, jhanji2024dynamicregulationof pages 4-7)

The following compact table summarizes the knowledge-base-level conclusions.

Table: Compact knowledge-base table summarizing identifiers, genetics, phenotypes, mechanism, diagnosis, management, models, and current evidence gaps for Intellectual disability, autosomal dominant 52 / ASH1L-related disorder. It separates established disease knowledge from preclinical and preprint findings.

1. Disease information

Definition. MRD52 is a monogenic developmental disorder in which deficient ASH1L dosage disrupts chromatin-dependent neuronal development. It belongs to the Mendelian intellectual-developmental disorders and more broadly to the “chromatinopathies.” Reported severity ranges from mild to severe intellectual disability, with developmental and speech delay, autism-spectrum manifestations, and variable dysmorphism. (wilson2022reprogrammingofthe pages 14-15)

Identifiers and names

• MONDO: MONDO:0030918.
• OMIM phenotype: 617796, Intellectual disability, autosomal dominant 52.
• Common abbreviations/synonyms: MRD52; ASH1L-related intellectual developmental disorder; ASH1L-related neurodevelopmental disorder.
• Gene: ASH1L, also called KMT2H; Ensembl ENSG00000116539.
• A unique disease-specific ICD-10, ICD-11, or MeSH code was not established in the retrieved evidence; patients are ordinarily coded under intellectual disability, developmental disorder, autism, or epilepsy as appropriate.

Open Targets associates ASH1L with MONDO:0030918 and links the association to, among other studies, PMID 28394464, 23033978, and 28191889. It also returned a weaker LMAN2L association, but the present phenotype’s established molecular definition is ASH1L-related; the weaker result should not be used as an alternative causal assignment without re-curation. (OpenTargets Search: Intellectual disability, autosomal dominant 52)

The evidence is aggregated disease-level evidence from sequencing cohorts, case reports, curated databases, reviews, and experimental studies—not an analysis of an individual patient’s EHR.

2. Etiology, risk, protection, and environment

Causal factor

The primary cause is a germline heterozygous pathogenic ASH1L variant. Protein-truncating nonsense, frameshift, and splice-disrupting alleles are consistent with loss of function and haploinsufficiency; damaging catalytic-domain alleles can similarly impair histone methyltransferase activity. The experimentally modeled p.Glu2148Ter (E2148*) allele is a catalytic-domain truncation associated with ASD, ID, and epilepsy. (jhanji2024dynamicregulationof pages 4-7, jhanji2024dynamicregulationof pages 1-4)

Risk factors

• Genetic: carrying a pathogenic ASH1L allele is the principal risk factor. Most recognized cases appear sporadic/de novo, although autosomal-dominant transmission is biologically possible.
• Family history: an affected heterozygous parent would imply a 50% transmission probability per pregnancy, subject to variable expressivity. If apparently de novo, recurrence is low but not zero because parental germline mosaicism cannot be excluded.
• Modifiers: no validated modifier gene, founder allele, ancestry-specific risk, sex-specific penetrance, or polygenic modifier has been established.

No reliable disease-specific environmental, lifestyle, occupational, infectious, maternal-age, or sex risk factor has been demonstrated. Prenatal exposures associated with neurodevelopmental disorders generally should not be represented as causes or modifiers of molecularly confirmed MRD52 without direct evidence.

Protective factors and gene–environment interaction

No protective ASH1L allele, diet, drug, lifestyle exposure, or reproducible gene–environment interaction is known. Ordinary developmental supports may improve function but do not prevent the genotype. Infectious and zoonotic causation are not applicable.

3. Phenotypes

Because published cohorts are small and ascertainment differs, robust percentages are unavailable. Qualitative frequencies should therefore be encoded as “common,” “variable,” or “reported,” not as inferred percentages.

• Global developmental delay — HP:0001263: typically evident in infancy or early childhood; variable severity; chronic rather than episodic. It affects acquisition of communication, learning, self-care, and adaptive skills.
• Intellectual disability — HP:0001249: mild through severe; generally lifelong and non-remitting. Formal severity may become clearer during childhood as cognitive demands increase. (wilson2022reprogrammingofthe pages 14-15)
• Delayed speech and language development — HP:0000750; absent speech, if applicable — HP:0001344: often especially prominent. Childhood apraxia of speech has also been discussed within the expanding genetic spectrum of ASH1L-associated speech disorders, but should be assigned only after specialist motor-speech assessment.
• Autism/autistic behavior — HP:0000729 or HP:0000717: social-communication impairment, restricted interests, repetitive behavior, or formal ASD may occur. Behavioral consequences can substantially affect education, family participation, and independent living. (wilson2022reprogrammingofthe pages 14-15, jhanji2024dynamicregulationof pages 1-4)
• Seizures/epilepsy — HP:0001250 / HP:0001251: variably reported rather than obligatory. The experimental literature particularly supports susceptibility to absence-like and convulsive seizures, but mouse seizure type should not automatically be assigned to every patient. (ma2024chemogeneticinhibitionof pages 12-13)
• Hypotonia — HP:0001252: reported in the clinical spectrum and may contribute to delayed motor milestones, poor coordination, feeding difficulty, or need for physical therapy.
• Facial dysmorphism — HP:0001999: variable and generally nonspecific; it is not sufficiently distinctive to diagnose the disorder clinically. (wilson2022reprogrammingofthe pages 14-15)
• Other neuropsychiatric associations: ASH1L variation has been reported across ADHD, Tourette syndrome, schizophrenia, ASD, ID, and epilepsy. These broader associations demonstrate pleiotropy but are not all defining manifestations of MRD52. The 2024 preprint catalogued 136 disease-associated ASH1L variants across these phenotypes. (jhanji2024dynamicregulationof pages 1-4)

No disease-specific laboratory abnormality, metabolite signature, immune phenotype, or pathognomonic MRI pattern is established. Quality-of-life studies using EQ-5D, SF-36, PROMIS, or a disease-specific instrument were not found; impact must presently be inferred from communication, cognitive, behavioral, and seizure burden.

4. Genetic and molecular information

ASH1L encodes a large nuclear chromatin regulator and histone lysine methyltransferase. The dominant disease mechanism is best represented as haploinsufficiency/loss of function, although individual missense variants require case-specific functional and ACMG/AMP assessment. Disease-associated classes include nonsense, frameshift, splice, and damaging missense/catalytic-domain variants. (wilson2022reprogrammingofthe pages 14-15, jhanji2024dynamicregulationof pages 4-7)

For a knowledge base, each variant should retain transcript-specific HGVS nomenclature, genome build, inheritance, ClinVar assertion and review status, and gnomAD frequency. Pathogenic truncating alleles are expected to be absent or extremely rare in population databases, but no universal allele frequency can be assigned without variant-level lookup. The variants are germline, not a recognized somatic cancer mechanism in this disease.

No validated modifier genes or MRD52-specific diagnostic DNA-methylation episignature were identified. ASH1L can be affected within larger copy-number alterations, but a broad deletion involving neighboring genes should not be assumed phenotypically equivalent to an intragenic ASH1L loss-of-function allele.

5. Environmental, lifestyle, and infectious information

MRD52 is not known to be caused by toxins, radiation, pollution, occupation, smoking, alcohol, diet, inactivity, or infection. Such exposures can independently influence development or pregnancy outcome but have no demonstrated disease-specific causal interaction with ASH1L. There is no vaccine, antimicrobial prophylaxis, or environmental remediation specific to MRD52.

6. Mechanism and pathophysiology

Upstream molecular defect

ASH1L promotes active chromatin through H3K36me2 and associated H3K4me3 and counteracts PRC2-mediated H3K27me3 repression. It is expressed in embryonic and adult brain and participates in developmental gene activation, including HOX regulation. Suggested terms include GO:0018024, histone H3-K36 methylation; GO:0046968, histone H3-K4 methylation; GO:0006357, regulation of transcription by RNA polymerase II; and GO:0046975, histone methyltransferase activity. (wilson2022reprogrammingofthe pages 14-15, jhanji2024dynamicregulationof pages 1-4)

Causal chain

Pathogenic heterozygous ASH1L variant → reduced functional methyltransferase dosage/activity → altered H3K36/H3K4 and Polycomb-related chromatin states → inefficient transcription and altered isoform use of long neuronal, axonal, ion-channel, and synaptic genes → impaired neurite growth, neuronal connectivity, and excitation/inhibition balance → developmental delay, ID, autism-related behavior, speech impairment, and seizure susceptibility. Human patient-level genotype–mechanism correspondence remains less mature than the experimental evidence. (jhanji2024dynamicregulationof pages 4-7, jhanji2024dynamicregulationof pages 7-10, jhanji2024dynamicregulationof pages 10-12)

2024 human-neuron findings—preprint evidence

CRISPR-engineered human cortical excitatory neurons carrying E2148 showed mean neurite length of 47.47 ± 1.99 μm versus 56.9 ± 2.41 μm in controls (P<0.004), total neurite length of 139.3 ± 4.66 μm versus 182.7 ± 6.39 μm (P<0.0001), and a lower complexity index, 228.8 ± 13.42 versus 289.5 ± 18.21* (P<0.0099). (jhanji2024dynamicregulationof pages 26-29)

The same system showed H3K36me2 at 67%, H3K4me3 at 68%, and H3K36me3 at 78% of control. Nascent-transcription signal fell from 1.017 ± 0.029 to 0.817 ± 0.027 (P<0.0001). Transcriptomic analysis identified 2,475 differentially expressed genes in one analysis, with enrichment for axon guidance, axonogenesis, nervous-system development, transcription, and synaptic function; 263 dysregulated genes overlapped SFARI ASD genes. Long genes above 100 kb were preferentially downregulated, and 57 genes showed differential transcript usage, including SMARCA4, AFF2, and TARDBP. These findings are important but came from a December 2, 2024 bioRxiv preprint and require independent peer-reviewed replication. URL: https://doi.org/10.1101/2024.12.02.625500. (jhanji2024dynamicregulationof pages 4-7, jhanji2024dynamicregulationof pages 7-10, jhanji2024dynamicregulationof pages 10-12, jhanji2024dynamicregulationof pages 29-34)

Cellular systems

Relevant processes include axonogenesis (GO:0007409), neuron projection development (GO:0031175), synapse organization (GO:0050808), regulation of membrane potential (GO:0042391), and nervous-system development (GO:0007399). Principal suggested cell terms are neuron (CL:0000540), glutamatergic neuron (CL:0000679), and pyramidal neuron (CL:0002608). No convincing primary metabolic, immune, inflammatory, fibrotic, ischemic, or degenerative mechanism has been demonstrated.

7. Anatomical structures affected

The principal organ is the brain (UBERON:0000955), particularly the cerebral cortex (UBERON:0001870). Mouse electrophysiology implicates the prefrontal cortex (UBERON:0000451), where Ash1l haploinsufficiency increases pyramidal-neuron excitability through enhanced glutamatergic transmission, reduced GABAergic inhibition, and altered intrinsic properties. Relevant subcellular compartments include nucleus (GO:0005634), chromatin (GO:0000785), axon (GO:0030424), dendrite (GO:0030425), and synapse (GO:0045202). (ma2024chemogeneticinhibitionof pages 12-13)

No consistent lateralization is known. Dysmorphic or skeletal findings may occur, but nervous-system dysfunction is primary.

8. Temporal development and natural history

The molecular defect is present from conception and acts during prenatal and postnatal neurodevelopment. Clinical recognition is usually pediatric and insidious—through delayed milestones, language delay, hypotonia, behavior, or seizures—rather than an acute onset. MRD52 is chronic and lifelong; there is no established staging system, remission pattern, or end-stage phase. Developmental gains may occur with maturation and therapy, but underlying intellectual and adaptive impairment generally persists. Longitudinal studies are insufficient to determine whether epilepsy, behavior, or cognition systematically improves or worsens with age.

Early childhood is likely the most important intervention window because language, motor, and social circuits are developing, although no ASH1L-specific critical-period trial has established an optimal time.

9. Inheritance and population

Inheritance is autosomal dominant (HP:0000006), with many diagnoses arising from de novo variants. Expressivity is variable; penetrance has not been accurately quantified. Anticipation, repeat expansion, consanguinity, a founder effect, and a carrier frequency are not established features. Germline mosaicism remains a counseling consideration after an apparently de novo result.

The disease is ultra-rare, but no defensible incidence per 100,000, prevalence, geographic concentration, ethnic enrichment, age distribution, or sex ratio was found. Absence of epidemiologic estimates reflects limited ascertainment rather than proof of equal distribution.

10. Diagnostics

Recommended approach

1. Perform clinical developmental, neurologic, behavioral, speech-language, hearing, vision, growth, and dysmorphology assessment.
2. Use trio exome sequencing or genome sequencing, or a comprehensive developmental-delay/ID/epilepsy panel containing ASH1L. Trio analysis helps establish de novo status and reduces uncertainty.
3. Confirm reportable variants by an orthogonal method where required and test both parents. Apply ACMG/AMP criteria, including predicted loss of function, population absence, segregation, phenotype fit, and functional evidence.
4. Use chromosomal microarray when copy-number disease remains possible; genome sequencing may detect both sequence and structural variants. Karyotype or FISH is indicated only when a larger rearrangement is suspected.
5. Consider RNA sequencing for a suspected splice variant or unresolved case, but it is not a routine validated MRD52 diagnostic biomarker.

No enzyme assay, blood biomarker, metabolomic test, biopsy, liquid biopsy, or established epigenomic signature diagnoses MRD52. MRI and EEG are phenotype-directed: MRI for focal neurologic signs, abnormal head growth, regression, or seizures; EEG for suspected seizures or developmental regression. Mitochondrial and repeat-expansion testing are not disease-specific.

Differential diagnosis

The differential includes other chromatinopathies and monogenic NDDs—SETD5-, KMT2A-, KMT2D-, KDM5B-, CHD8-, ARID1B-, ASXL3-, TCF4-, and FOXP-related disorders—as well as Fragile X syndrome, pathogenic CNVs, metabolic disease when clinically indicated, cerebral palsy, nonsyndromic ASD/ID, and epilepsy-associated developmental encephalopathies. Clinical overlap is substantial, making genome-wide testing preferable to phenotype-only diagnosis.

11. Outcome and prognosis

No disease-specific five- or ten-year survival, mortality rate, or life-expectancy estimate is available. Available evidence does not establish MRD52 as intrinsically life-limiting, but severe epilepsy, feeding problems, accidents, or unrelated congenital disease could influence individual prognosis.

The major morbidity is lifelong impairment of cognition, communication, adaptive function, education, employment, and independent living. Prognosis is likely influenced by intellectual-disability severity, functional speech, epilepsy control, hypotonia/motor impairment, ASD/behavioral burden, and access to early services. No validated molecular prognostic biomarker exists.

12. Treatment and current applications

There is no approved ASH1L-directed therapy and no disease-specific treatment-response rate. Current real-world implementation is genotype-informed supportive care:

• individualized education and early developmental intervention;
• speech-language therapy, including augmentative and alternative communication when needed;
• occupational and physical therapy;
• behavioral and ASD-focused interventions;
• standard antiseizure treatment selected by seizure type and tolerability;
• feeding, sleep, psychiatric, hearing, vision, and orthopedic management as indicated;
• social-work, respite, and transition-to-adult-care planning.

Suggested NCIT annotations include Supportive Care (NCIT:C51909), Speech Therapy (NCIT:C17556), Occupational Therapy (NCIT:C15635), Physical Therapy (NCIT:C15313), and Behavioral Intervention (NCIT:C146712).

Experimental therapy

In Ash1l+/GT mice, chemogenetic inhibition of prefrontal pyramidal neurons improved social deficits and abolished absence-like seizures, indicating that cortical hyperexcitability is modifiable. This DREADD experiment is mechanistic and is not a clinically available treatment. URL and publication date: Genes, December 2024, https://doi.org/10.3390/genes15121619. (ma2024chemogeneticinhibitionof pages 12-13)

In engineered human neurons, tazemetostat (EZH2 inhibitor, 0.5 μM) and vorinostat (HDAC inhibitor, 0.1 μM) improved selected neurite/chromatin readouts. Vorinostat increased total neurite length from 163.3 ± 4.83 μm under vehicle to 225.2 ± 8.38 μm and markedly increased H4K16ac; tazemetostat reduced H3K27me3. These agents have substantial systemic effects and are not recommended for MRD52 outside ethically approved research. (jhanji2024dynamicregulationof pages 34-39, jhanji2024dynamicregulationof pages 39-41)

No ASH1L-specific gene replacement, CRISPR, ASO, siRNA, mRNA, cell therapy, immunotherapy, surgery, pharmacogenomic rule, or registered interventional trial was identified.

13. Prevention

The genotype cannot be prevented by lifestyle change, vaccination, or prophylactic medication. Appropriate measures are:

• Primary reproductive prevention: genetic counseling, parental testing, discussion of recurrence risk, prenatal diagnosis, and preimplantation genetic testing for a known familial pathogenic variant.
• Secondary prevention: prompt etiologic sequencing in unexplained DD/ID and early developmental, speech, hearing, and seizure assessment.
• Tertiary prevention: therapies and surveillance intended to limit communication disability, contractures/deconditioning, behavioral crisis, untreated epilepsy, sleep disruption, and caregiver burden.
• Cascade testing: appropriate if a pathogenic variant is inherited; routine population or newborn screening is not currently justified.

14. Other species and natural disease

No well-characterized naturally occurring veterinary counterpart, breed predisposition, animal-to-human transmission, or zoonotic risk was identified. Relevant orthologs are Ash1l in mouse (Mus musculus, NCBI Taxon 10090) and ash1-family orthologs in zebrafish (Danio rerio, NCBI Taxon 7955). Conservation of chromatin regulation and neuronal-development functions makes these experimentally informative, but engineered phenotypes are not natural animal disease.

15. Model organisms and experimental systems

Mouse, gene-trap haploinsufficiency. Ash1l+/GT mice exhibited social deficits, increased self-grooming, cognitive impairment, EEG epileptiform discharges/absence-like seizures, and increased pentylenetetrazole susceptibility. Whole-cell recordings showed hyperexcitable prefrontal pyramidal neurons, enhanced glutamatergic transmission, and diminished GABAergic inhibition. This is the strongest recent peer-reviewed mechanistic model, but mouse social behavior and chemogenetic rescue do not directly predict human treatment efficacy. (ma2024chemogeneticinhibitionof pages 12-13)

Human cellular model. Isogenic pluripotent-stem-cell-derived cortical excitatory neurons carrying E2148* reproduced impaired neurite outgrowth, simpler arbors, altered H3K36/H3K4 regulation, reduced transcription, long-gene vulnerability, and isoform changes. Its human genetic background and cell-type specificity are strengths; lack of organismal development, glial circuitry, pharmacokinetics, and peer review are limitations. (jhanji2024dynamicregulationof pages 4-7, jhanji2024dynamicregulationof pages 7-10, jhanji2024dynamicregulationof pages 26-29)

Zebrafish and other mouse alleles. Zebrafish ash1a knockdown reportedly reduces pineal neuron number, while catalytically inactive Ash1l mice have skeletal anomalies and impaired fertility. These models support developmental conservation but only partially reproduce the human neurobehavioral syndrome. (wilson2022reprogrammingofthe pages 14-15)

Authoritative interpretation and evidence gaps

The current expert interpretation is that MRD52 is best understood as a developmental chromatin-regulation disorder, not simply isolated intellectual disability. The convergence of human genetics, neuronal chromatin/transcriptomic data, and mouse electrophysiology supports a model in which altered epigenetic regulation produces abnormal neuronal connectivity and cortical excitation/inhibition. However, the field remains constrained by small clinical cohorts, heterogeneous variant ascertainment, limited longitudinal phenotyping, and a lack of patient-derived functional studies in peer-reviewed literature. The 2024 human-neuron work is promising but is a preprint; its epigenetic-drug rescues should be treated as hypothesis-generating rather than therapeutic evidence. (wilson2022reprogrammingofthe pages 14-15, jhanji2024dynamicregulationof pages 1-4, jhanji2024dynamicregulationof pages 39-41)

Two concise source statements capture the current evidence:

“Clinical phenotypes in MRD52 individuals include mild-severe intellectual disability, autism spectrum disorder, speech delay, facial dysmorphisms, and developmental delay.” — synthesis of the peer-reviewed chromatin/NDD review, published October 2022, https://doi.org/10.1080/10409238.2021.1979457. (wilson2022reprogrammingofthe pages 14-15)

“Chemogenetic inhibition of pyramidal neurons in the PFC of Ash1l+/GT mice ameliorated autism-like social deficits and abolished absence-like seizures.” — Ma et al., published December 2024, https://doi.org/10.3390/genes15121619. (ma2024chemogeneticinhibitionof pages 12-13)

Accordingly, immediate clinical value lies in molecular diagnosis, recurrence counseling, anticipatory neurologic/developmental care, and access to individualized services. Disease-modifying treatment, validated natural-history endpoints, and prospective genotype–phenotype statistics remain priority research needs.

References

1. (ma2024chemogeneticinhibitionof pages 12-13): Kaijie Ma, Kylee McDaniel, Daoqi Zhang, Maria Webb, and Luye Qin. Chemogenetic inhibition of prefrontal cortex ameliorates autism-like social deficits and absence-like seizures in a gene-trap ash1l haploinsufficiency mouse model. Genes, 15(12):1619, Dec 2024. URL: https://doi.org/10.3390/genes15121619, doi:10.3390/genes15121619. This article has 2 citations.

2. (wilson2022reprogrammingofthe pages 14-15): Khadija D. Wilson, Elizabeth G. Porter, and Benjamin A. Garcia. Reprogramming of the epigenome in neurodevelopmental disorders. Critical Reviews in Biochemistry and Molecular Biology, 57:73-112, Oct 2022. URL: https://doi.org/10.1080/10409238.2021.1979457, doi:10.1080/10409238.2021.1979457. This article has 33 citations and is from a peer-reviewed journal.

3. (jhanji2024dynamicregulationof pages 4-7): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

4. (OpenTargets Search: Intellectual disability, autosomal dominant 52): Open Targets Query (Intellectual disability, autosomal dominant 52, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (jhanji2024dynamicregulationof pages 1-4): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

6. (jhanji2024dynamicregulationof pages 10-12): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

7. (jhanji2024dynamicregulationof pages 39-41): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

8. (jhanji2024dynamicregulationof pages 34-39): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

9. (jhanji2024dynamicregulationof pages 26-29): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

10. (jhanji2024dynamicregulationof pages 7-10): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

11. (jhanji2024dynamicregulationof pages 29-34): Megha Jhanji, Joseph A. Ward, Calvin S. Leung, Colleen L. Krall, Foster D. Ritchie, Alexis Guevara, Kai Vestergaard, Brian Yoon, Krishna Amin, Stefano Berto, Judy S. Liu, and Sofia B. Lizarraga. Dynamic regulation of the chromatin environment by ash1l modulates human neuronal structure and function. bioRxiv, Dec 2024. URL: https://doi.org/10.1101/2024.12.02.625500, doi:10.1101/2024.12.02.625500. This article has 0 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.